尼可地尔联合水化预防冠状动脉介入术后对比剂肾病的临床疗效

doi:10.3760/cma.j.issn.1007-1245.2023.24.025

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (24): 3645-3648.DOI: 10.3760/cma.j.issn.1007-1245.2023.24.025

尼可地尔联合水化预防冠状动脉介入术后对比剂肾病的临床疗效

何海燕¹ 芦菲²

¹徐州医科大学附属徐州市立医院心血管内科，徐州　221000；²中国人民解放军陆军第71集团军医院急诊科，徐州　221004

收稿日期:2023-07-20 出版日期:2023-12-15 发布日期:2024-01-04
通讯作者: 何海燕，Email：hhylf9519@163.com
基金资助:
徐州市第一人民医院“青苗工程”（QMBJ2021007）

Nicorandil combined with hydration in prevention of contrast-induced nephropathy after percutaneous coronary intervention

He Haiyan¹, Lu Fei²

¹Department of Cardiology, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou 221000, China; ²Department of Emergency Medicine, 71st Group Army Hospital of CPLA Army, Xuzhou 221004, China

Received:2023-07-20 Online:2023-12-15 Published:2024-01-04
Contact: He Haiyan, Email: hhylf9519@163.com
Supported by:
Young Crop Program of Xuzhou First People's Hospital (QMBJ2021007)

摘要/Abstract

摘要：

目的　探讨在水化治疗基础上联合应用尼可地尔对冠心病患者经皮冠状动脉介入（percutaneous coronary intervention，PCI）术后对比剂肾病（contrast-induced nephropathy，CIN）的发生率，并观察其临床效果。方法　选取2022年1月至2023年4月在徐州医科大学附属徐州市立医院心血管内科行PCI治疗的200例冠心病患者，分为对照组和尼可地尔组，各100例。对照组中，男59例，女41例，年龄（64.33±10.24）岁，仅使用水化方案；尼可地尔组中，男55例，女45例，年龄（65.11±10.21）岁，在水化治疗的基础上加用尼可地尔预防CIN的发生。所有入选患者分别于术前、术后行血清肌酐（Scr）、血清胱抑素C（CysC）等相关检查，计算估测肾小球滤过率（eGFR）。观察两组患者血清Scr、CysC、eGFR变化及CIN发生率、严重心血管不良事件的发生情况。采用t、χ²检验或Fisher确切概率进行统计分析。结果　200例患者中，有17例（8.5%）发生CIN，其中对照组13例（13.0%，13/100），尼可地尔组4例（4.0%，4/100），两组CIN的发生率差异有统计学意义（P<0.05）。治疗后，尼可地尔组术后血清Scr、CysC低于对照组，eGFR高于对照组，差异均有统计学意义（均P<0.05）。所有患者均未出现严重的心血管不良事件。结论　在水化治疗的基础上，联合应用尼可地尔可降低PCI术后CIN的发生率，且无严重心血管不良事件发生。

关键词:

冠心病, 对比剂肾病, 尼可地尔, 水化, 经皮冠状动脉介入, 预防

Abstract:

Objective　To evaluate the safety and efficacy of nicorandil combined with hydration therapy in the prevention of contrast-induced nephropathy (CIN) in coronary heart disease patients after percutaneous coronary intervention (PCI). Methods　Two hundred patients with coronary heart disease treated in Department of Cardiology, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University from January 2022 to April 2023 were randomly divided into a control group and a nicorandil group, with 100 cases in each group. There were 59 males and 41 females in the control group; they were (64.33±10.24) years old. There were 55 males and 45 females in the nicorandil group; they were (65.11±10.21) years old. The control group were treated only with hydration, while the nicorandil group with nicorandil and hydration. Serum creatinine (Scr) and cystatin C (CysC) were tested in all the enrolled patients before and after the operation. The estimated glomerular filter rate (eGFR) was calculated. The changes in the serum levels of Scr and CysC and eGFR, as well as the incidences of CIN and serious adverse cardiovascular events, were observed in both groups. t test, χ² test, and Fisher exact probability test were used for the statistical comparisons. Results　There were 17 cases (8.5%) of CIN among the 200 patients, including 13 cases (13.0%) in the control group and 4 cases (4.0%) in the nicorandil group. There was a statistical difference in the incidence of CIN between the two groups (P<0.05). Compared with the control group, the nicorandil group had low lower serum levels of Scr and CysC and higher eGFR after the operation, with statistical differences (all P<0.05). No serious adverse cardiovascular events occurred in the patients. Conclusion　Nicorandil combined with hydration can reduce the incidence of CIN after PCI, with no serious cardiovascular adverse events.

Key words:

Coronary heart disease, Contrast-induced nephropathy, Nicorandil, Hydration therapy, Percutaneous coronary intervention, , Prevention

何海燕芦菲.

尼可地尔联合水化预防冠状动脉介入术后对比剂肾病的临床疗效 [J]. 国际医药卫生导报, 2023, 29(24): 3645-3648.

He Haiyan, Lu Fei.

Nicorandil combined with hydration in prevention of contrast-induced nephropathy after percutaneous coronary intervention [J]. International Medicine and Health Guidance News, 2023, 29(24): 3645-3648.

参考文献

[1] 刘超群,余琴,刘顺民,等.冠心病介入治疗患者血尿肾损伤标志物与对比剂肾病关系及不良事件预测价值[J].中国心血管病研究,2022,20(7):608-614.DOI:10.3969/j.issn.1672-5301.2022.07.004.
[2] Moro AB, Strauch JGN, Groto AD, et al. Creatinine level variation in patients subjected to contrast-enhanced tomography: a meta-analysis[J]. J Vasc Bras, 2021,20:e20200161. DOI: 10.1590/1677-5449.200161.
[3] Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy[J]. J Am Soc Nephrol, 2000,11(1):177-182. DOI: 10.1681/ASN.V111177.
[4] Hossain MA, Costanzo E, Cosentino J, et al. Contrast-induced nephropathy: pathophysiology, risk factors, and prevention[J]. Saudi J Kidney Dis Transpl, 2018,29(1):1-9. DOI: 10.4103/1319-2442.225199.
[5] Chandiramani R, Cao D, Nicolas J, et al. Contrast-induced acute kidney injury[J]. Cardiovasc Interv Ther, 2020,35(3):209-217. DOI: 10.1007/s12928-020-00660-8.
[6] 陈璐,王用,邢玉龙,等.不同方案对老年冠心病并轻度肾功能不全患者择期经皮冠状动脉介入治疗后对比剂肾病的预防效果及其影响因素研究[J].实用心脑肺血管病杂志,2021,29(7):110-114,120.DOI:10.12114/j.issn.1008- 5971. 2021.00.134.
[7] Nijssen EC, Nelemans PJ, Rennenberg RJ, et al. Impact on clinical practice of updated guidelines on iodinated contrast material: CINART[J]. Eur Radiol, 2020,30(7):4005-4013. DOI: 10.1007/s00330-020-06719-7.
[8] 康杰,张建建,张伟东,等.尼可地尔联合二甲双胍治疗2型糖尿病合并冠心病患者的疗效和安全性观察[J].国际医药卫生导报,2023,29(7):936-939.DOI:10.3760/cma.j.issn.1007-1245.2023.07.011.
[9] 李晶,李雨涵,申国旗,等.sd-LDL联合NT-proBNP对急性STEMI患者经皮冠状动脉介入治疗术后CI-AKI的预测价值[J].医学研究杂志,2022,51(10):132-137.DOI:10.11969/j.issn.1673-548X.2022.10.029.
[10] Zhang F, Lu Z, Wang F. Advances in the pathogenesis and prevention of contrast-induced nephropathy[J]. Life Sci, 2020,259:118379. DOI: 10.1016/j.lfs.2020.118379.
[11] Ma X, Li X, Jiao Z, et al. Nicorandil for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials. Cardiovasc Ther. 2018 Apr;36(2). DOI: 10.1111/1755-5922.12316.
[12] Hernandez-Vaquero D, Diaz R, Alperi A, et al. Life expectancy of patients undergoing surgical aortic valve replacement compared with that of the general population[J]. Interact Cardiovasc Thorac Surg, 2020,30(3):394-399. DOI: 10.1093/icvts/ivz268.
[13] Bansal S, Patel RN. Pathophysiology of contrast-induced acute kidney injury[J]. Interv Cardiol Clin, 2020,9(3):293-298. DOI: 10.1016/j.iccl.2020.03.001.
[14] Fang D, Wang Y, Zhang Z, et al. Calorie restriction protects against contrast-induced nephropathy via SIRT1/GPX4 activation[J]. Oxid Med Cell Longev, 2021,2021:2999296. DOI: 10.1155/2021/2999296.
[15] 海峡两岸医药卫生交流协会护理分会心血管护技专业学组.心血管介入碘对比剂使用管理护理专家共识[J].中国循环杂志,2021,36(7):625-633.DOI:10.3969/j.issn.1000- 3614.2021.07.001.
[16] Goel H, Carey M, Elshaikh A, et al. Cardioprotective and antianginal efficacy of nicorandil: a comprehensive review[J]. J Cardiovasc Pharmacol, 2023,82(2):69-85. DOI: 10.1097/FJC.0000000000001436.
[17] Zhu Y, Xie S. Intravenous nicorandil for patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials[J]. Scand Cardiovasc J, 2023,57(1):2220556. DOI: 10.1080/14017431.2023.2220556.
[18] Ilyas M, Noor M, Khan HS, et al. Cardio protective effect of nicorandil in reperfusion injury among patients undergoing primary percutaneous coronary intervention[J]. Pak J Med Sci, 2023,39(1):177-181. DOI: 10.12669/pjms.39.1.6034.
[19] Sun Z, Zhang X, Ito K, et al. Amelioration of oxidative mitochondrial DNA damage and deletion after renal ischemic injury by the KATP channel opener diazoxide[J]. Am J Physiol Renal Physiol, 2008,294(3):F491-498. DOI: 10.1152/ajprenal.00263.2007.
[20] Zeng Z, Fu X, Zhang X, et al. Comparison of double-dose vs. usual dose of nicorandil for the prevention of contrast-induced nephropathy after cardiac catheterization[J]. Int Urol Nephrol, 2019,51(11):1999-2004. DOI: 10.1007/s11255-019-02244-9.
[21] 宫颖,梁明亭,赵京飞,等.静脉应用尼可地尔对冠心病患者冠脉介入治疗后对比剂肾病的影响[J].中国分子心脏病学杂志,2021,21(5):4232-4235.DOI:10.16563/j.cnki.1671-6272.2021.10.018.
[22] Zhang P, Li WY, Yang SC, et al. Preventive effects of nicorandil against contrast-induced nephropathy in patients with moderate renal insufficiency undergoing percutaneous coronary intervention[J].Angiology,2020,71(2):183-188.DOI: 10.1177/0003319719841733.

尼可地尔联合水化预防冠状动脉介入术后对比剂肾病的临床疗效

Nicorandil combined with hydration in prevention of contrast-induced nephropathy after percutaneous coronary intervention

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	叶凤翔刘栋涛范子晨. PCI术中应用药物涂层球囊对冠心病不稳定性心绞痛患者的临床疗效 [J]. 国际医药卫生导报, 2024, 30(1): 57-62.
[2]	李瑜萍黄育娜朱进华陈国兴林艳霞. 替格瑞洛与氯吡格雷在急性心肌梗死患者经皮冠状动脉介入中的效果 [J]. 国际医药卫生导报, 2024, 30(1): 109-111.
[3]	康杰张建建张伟东张岳黄杲德. 尼可地尔联合二甲双胍治疗2型糖尿病合并冠心病患者的疗效和安全性观察 [J]. 国际医药卫生导报, 2023, 29(7): 936-939.
[4]	韦颖莫昌干韦利元贝晓娜赖冬艳唐秀革. 新型心脏康复训练对急性ST段抬高型心肌梗死患者PCI术后心功能及血管内皮功能的影响 [J]. 国际医药卫生导报, 2023, 29(4): 537-541.
[5]	任浩王惠林王磊. 血清淀粉样蛋白A联合胱抑素C、脂蛋白a对冠心病患者经皮冠状动脉介入治疗后冠状动脉再狭窄的预测价值 [J]. 国际医药卫生导报, 2023, 29(3): 419-423.
[6]	黄韵诗杨燕君吴少敏吴嘉婷. 广州市番禺区儿童家长水痘疫苗犹豫现状及其影响因素分析 [J]. 国际医药卫生导报, 2023, 29(24): 3732-3735.
[7]	骆美仪李红霞. 管道滑脱风险评估表在ICU非计划性拔管防范中的应用 [J]. 国际医药卫生导报, 2023, 29(21): 3112-3115.
[8]	刘朝阳周付娇. 甲状腺功能与冠心病患者病情进展的关联研究 [J]. 国际医药卫生导报, 2023, 29(18): 2601-2605.
[9]	潘海萍何平. 示警性预防护理对重症肺炎患者风险系数及临床结局的影响 [J]. 国际医药卫生导报, 2023, 29(17): 2494-2498.
[10]	徐希李向阳张波向远刚阳攀张振声许传亮. 预防膀胱癌患者发生静脉血栓栓塞的研究进展 [J]. 国际医药卫生导报, 2023, 29(15): 2073-2076.
[11]	李晶周晶潘三葱. 探究miR-374a-5p与急性ST段抬高型心肌梗死患者PCI后6个月内支架内血栓形成的关系 [J]. 国际医药卫生导报, 2023, 29(12): 1678-1682.
[12]	李晶孙爱臣王桂玲任倩倩王丹. 多维化个体护模式在老年冠心病患者中的应用 [J]. 国际医药卫生导报, 2023, 29(12): 1729-1733.
[13]	范鹏云. 24 h动态心电图参数评估急性心肌梗死患者PCI治疗后恶性心律失常的研究[J]. 国际医药卫生导报, 2022, 28(6): 863-866.
[14]	毛晓芬, 杨波, 唐莉, 龚婷婷, 左慧, 吴丽美. 某医院工作人员接种新冠灭活疫苗的回顾性研究[J]. 国际医药卫生导报, 2022, 28(4): 577-581.
[15]	袁琛烨, 周之音. 基于智慧医疗系统的管理模式预防乳腺癌患者术后淋巴水肿的效果观察 [J]. 国际医药卫生导报, 2022, 28(3): 336-340.